DT-109 reverses MASH in primates by repairing the gut
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- DT-109 reversed severe MASH in mice and nonhuman primates by reducing overgrowth of the bacterium Clostridium perfringens and lowering gut ammonia, restoring the intestinal barrier that normally keeps harmful microbial products out of the bloodstream.
- The nonhuman primate results were particularly encouraging — DT-109 significantly reduced liver inflammation and improved MASH severity in animals whose gut biology more closely resembles that of humans.
- MASH affects approximately 7% of people worldwide and can progress to cirrhosis, liver cancer, and liver failure, yet effective treatment options remain limited.
- The study, published in The Journal of Clinical Investigation, traced the disease pathway to ammonia from Clostridium perfringens damaging the gut lining and triggering excessive CD8+ T cell activation in the liver.
- Prior research found DT-109 reduced atherosclerosis plaque formation and prevented vascular calcification in nonhuman primates, suggesting possible cardiovascular applications beyond liver disease.
- The team flagged inflammatory bowel disease (IBD) as another potential target, given the broader link between intestinal barrier breakdown and digestive disorders.
- The University of Michigan has patented DT-109 and licensed it to Diapin Therapeutics, which supplied the compound and is continuing development toward clinical trials.
Why it matters: For the roughly 7% of people worldwide living with MASH — a disease that can progress to cirrhosis, liver cancer, and liver failure — DT-109 offers a new therapeutic angle by repairing the gut barrier rather than targeting the liver directly. With prior primate studies already showing cardiovascular benefits, the same compound could eventually address multiple diseases tied to gut barrier breakdown, though it still must clear human clinical trials.
